UK competition authority escalates investigation of Oticon Medical sale

Neither Demant not Cochlear has wanted to comment on the UK competition authority, which is therefore bringing its merger inquiry into phase II. 
Photo: Jens Dresling/Politiken/Ritzau Scanpix
Photo: Jens Dresling/Politiken/Ritzau Scanpix
by albert rønning-andersson, translated by daniel pedersen

The UK Competition and Markets Authority, CMA, expressed concerns earlier this month regarding Demant selling off its Oticon Medical division to Australian Cochlear. After both parties declined an invitation to comment, the inquiry is moving into phase II. Phase one started in back in October.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading